AR055584A1 - Procedimiento para preparar un oligomero entrecruzado covalentemente de peptidos beta amiloide - Google Patents

Procedimiento para preparar un oligomero entrecruzado covalentemente de peptidos beta amiloide

Info

Publication number
AR055584A1
AR055584A1 ARP060102726A ARP060102726A AR055584A1 AR 055584 A1 AR055584 A1 AR 055584A1 AR P060102726 A ARP060102726 A AR P060102726A AR P060102726 A ARP060102726 A AR P060102726A AR 055584 A1 AR055584 A1 AR 055584A1
Authority
AR
Argentina
Prior art keywords
oligomer
beta
amiloid
covalently
peptides
Prior art date
Application number
ARP060102726A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR055584A1 publication Critical patent/AR055584A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a un procedimiento para la preparacion de un oligomero entrecruzado estabilizado de beta amiloide usando un agente entrecruzador bifuncional para usar como inmunogeno para la generacion de anticuerpos para el tratamiento de enfermedad de Alzheimer y otras afecciones relacionadas con la agregacion anormal de beta amiloide. Un agente entrecruzador bifuncional preferido es 1,5-difluoro-2,4-dinitrobenceno (DFDNB).
ARP060102726A 2005-06-30 2006-06-23 Procedimiento para preparar un oligomero entrecruzado covalentemente de peptidos beta amiloide AR055584A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69552805P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
AR055584A1 true AR055584A1 (es) 2007-08-29

Family

ID=37478826

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102726A AR055584A1 (es) 2005-06-30 2006-06-23 Procedimiento para preparar un oligomero entrecruzado covalentemente de peptidos beta amiloide

Country Status (10)

Country Link
US (1) US20100143396A1 (es)
EP (1) EP1899371A2 (es)
JP (1) JP2009500325A (es)
CN (1) CN101213207A (es)
AR (1) AR055584A1 (es)
AU (1) AU2006266212A1 (es)
BR (1) BRPI0612897A2 (es)
CA (1) CA2613040A1 (es)
TW (1) TW200726482A (es)
WO (1) WO2007005358A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP5486808B2 (ja) 2005-11-30 2014-05-07 アッヴィ・インコーポレイテッド アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
NO347079B1 (no) 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Forbedrede protofibrilselektive antistoffer og anvendelse derav
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
FR2922769A1 (fr) * 2007-10-31 2009-05-01 Halina Malina Modification des sequences intrinsequement desordonnees pour la preparation de vaccins
CN102065881B (zh) 2008-04-14 2014-03-12 埃尔奇诺瓦公司 稳定的淀粉样beta单体和寡聚体
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
MX338640B (es) 2010-07-14 2016-04-25 Merck Sharp & Dohme Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos.
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
MA53887A (fr) 2014-07-10 2021-10-27 Bioarctic Ab Anticorps à liaison protofibrille a-bêta améliorée

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213718A1 (en) * 2002-03-01 2003-09-16 Szu-Yi Chou Method of producing antigens

Also Published As

Publication number Publication date
AU2006266212A1 (en) 2007-01-11
BRPI0612897A2 (pt) 2016-11-29
EP1899371A2 (en) 2008-03-19
CA2613040A1 (en) 2007-01-11
US20100143396A1 (en) 2010-06-10
WO2007005358A3 (en) 2007-04-05
WO2007005358A2 (en) 2007-01-11
JP2009500325A (ja) 2009-01-08
TW200726482A (en) 2007-07-16
CN101213207A (zh) 2008-07-02

Similar Documents

Publication Publication Date Title
AR055584A1 (es) Procedimiento para preparar un oligomero entrecruzado covalentemente de peptidos beta amiloide
BR112022002599A2 (pt) Vesícula extracelular ligada a moléculas e usos da mesma
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
BR112018009483A2 (pt) expansor biocompatível implantável adequado para o tratamento de constrições do lúmen do corpo
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
CR9749A (es) Derivados de xantina como agonistas de hm74a selectivos
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
ATE534378T1 (de) Titrierung von tapentadol
WO2003104273A3 (en) THERAPEUTIC EPITOPES AND THEIR USES
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
BRPI0513317A (pt) ciclosporinas para tratar doença de alzheimer
MX2010003497A (es) Metodo para tratar el cabello usando vapor.
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BRPI0605942A (pt) composição cosmética para o tratamento de fibras de queratina, dispositivo em aerossol, processo de tratamento cosmético, e, uso de uma composição cosmética
WO2021048619A3 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal